# A Phase 2 Study of ABSK021 in Patients With Advanced Pancreatic Cancer

> **NCT06111274** · PHASE2 · RECRUITING · sponsor: **Abbisko Therapeutics Co, Ltd** · enrollment: 82 (estimated)

## Conditions studied

- Advanced Pancreatic Cancer

## Interventions

- **DRUG:** Pimicotinib (ABSK021)

## Key facts

- **NCT ID:** NCT06111274
- **Lead sponsor:** Abbisko Therapeutics Co, Ltd
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2023-10-17
- **Primary completion:** 2025-12-30
- **Final completion:** 2026-12-29
- **Target enrollment:** 82 (ESTIMATED)
- **Last updated:** 2024-04-11


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06111274

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06111274, "A Phase 2 Study of ABSK021 in Patients With Advanced Pancreatic Cancer". Retrieved via AI Analytics 2026-06-03 from https://api.ai-analytics.org/clinical/NCT06111274. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*